NCT07473713

Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia

Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia: a Dose-finding Randomized Controlled Trial

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Tufts Medical Center · Academic / Other
• Sex: All
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are: * How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion. * Describe the safety of veverimer based on changes in serum bicarbonate and potassium. * Assess the changes in bone resorption. * Assess the changes in bone formation. * Explore the effect of veverimer on physical performance. Participants will: * Take veverimer or placebo every day or every other day for 8 weeks * Visit the clinic a total of 8 times (including screening) for checkups and testing * Keep a medication diary tracking each day they take the study drug

Conditions

• Osteopenia

Interventions

Type	Name	Description
DRUG	veverimer daily	8 weeks of taking 9 grams of veverimer (a powder mixed into water) daily
DRUG	veverimer every other day	8 weeks of taking 9 grams of veverimer (a powder mixed into water) every other day
OTHER	Placebo	8 weeks taking 9 grams microcrystalline cellulose (powdered mixed into water) daily or every other day

Timeline

• Start date: 2026-04-15
• Primary completion: 2028-03-01
• Completion: 2028-05-01
• First posted: 2026-03-16
• Last updated: 2026-04-06

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study